AgroAmerica Ranks Among the Top 10 of the Most Transparent Companies in Sustainable Palm Oil Practices in the World
AgroAmerica ranked as the 7th sustainable company out of 100 oil palm companies in the world. This year the company received a rating of 84.95% in the latest Sustainability Policy Transparency Toolkit (SPOTT) Assessment recently released by the UK-based Zoological Society of London (ZSL).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110006035/en/
AgroAmerica ranked in the top 10 out of 100 palm oil producers, processors, and traders on the public disclosure of their policies, operations, and commitments to environmental, social, and governance (ESG) best practice, in the results published by the renowned SPOTT Transparency evaluation. On the image, one of the most notable AgroAmerica's conservation project, The Maya Biosphere Conservation Project, that promotes the protection of 19,000+ hectares of land and the biodiversity of the area. (Photo: Business Wire)
The SPOTT platform promotes the transparency of companies by disclosing their policies, practices, and commitments related to environmental, social, and governance issues.
Fernando Bolaños, CEO of AgroAmerica, said that this is the third consecutive year that AgroAmerica participates in this sustainability evaluation, intending to improve, year after year, its practices and commitments, and continue to offer food products sustainably produced and distributed.
SPOTT evaluates 180 indicators grouped into 10 categories: Sustainability and leadership; Landbank, maps and traceability; Certification standards; Deforestation and biodiversity; HCV, HCS and impact assessments; Peat, fire and GHG emissions; Water, chemical and pest management; Community, land and labor rights; Smallholders and suppliers; Governance and grievances.
The evaluation aims to measure the progress of companies towards sustainable production and marketing of palm oil. Among the most notable results, AgroAmerica obtained the complete qualification in HCV, HCS and impact assessments, for its commitment to the conservation of ecosystems, especially in areas of High Conservation Value.
Additionally, its commitment to zero deforestation and the use of technological tools for the optimization of natural resources, as well as the implementation of programs and projects for compliance with labor and land rights and the verifiable establishment of good relations with communities, allowed AgroAmerica to be among the top 10 of the companies evaluated in the transparency ranking.
The SPOTT evaluation team, comprised of professionals from prestigious London universities, belongs to ZSL, and is part of the Palm Oil Roundtable (RSPO).
“Participating in this evaluation is part of our policy of being transparent in our sustainable production practices and reaffirming our commitment to comply with international standards, which leads us to differentiate ourselves and have a competitive advantage in the oil palm sector, as well as promote a sustainable production and trade, ”stated Bolaños.
About AgroAmerica
AgroAmerica is an agro-industrial company dedicated to the production and commercialization of food products, through sustainable and responsible methods. Our company has operations in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006035/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
(502) 2420-9600
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom